Cancer progression, following radical prostatectomy, is distinguished by its biological or clinical aspects and is a controversial subject. As adjuvant therapy there is hormonal treatment and radiation therapy or a combination of both. The lack of standardization of the main pathological features of prostate cancer does not allow an accurate valuation of the results from the most important studies. A real efficacy in local or distant control seems to be certain, while the influence on disease-free survival is more uncertain. After a review of the most common options of treatment, the Authors present their results from 107 radical prostatectomies carried out between 1989 and 1994.
AbbouC.C., LobelB.: Prostate Specific Antigen in the management of prostate caner. Romainville-France: Roussel Uclaf: 3–38, 1994.
2.
PrestigiacomoA., StameyT.A.: A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J. Urol., 152: 1515–1519, 1994.
3.
BonoA.V., Robustellidella Cuna G.: Carcinoma prostatico. Diagnosi e terapia. Pavia: Edizioni Medico Scientifiche, pp. 77–129, 1993.
4.
StameyT.A., McNealJ.: L'adenocarcinoma della prostata. In: Urologia di Campbell, Seconda edizione Italiana. Edito da WalshP.C., RetikA.B., StameyT.A, Darracott VaughanE., VerducciEditore Roma, vol. 2, capit. 29, pp. 1245–1262, 1993.
5.
BoccardoF., DecensiA., GuarnieriD.: Il carcinoma della Prostata. La terapia medica. Atti dei corsi paralleli. Genova: Scuola Superiore di Oncologia e Scienze Biomediche, pp. 67–151, 1991.
6.
BonoA., Di SilverioF., LottiT., PavoneMacaluso M., RoccaRossetti M.: Workshop on carcinoma prostatico. Roma: Intramed. Communication, pp. 23–52, 1994.
7.
McCarthyJ.F., CatalonaW.J., HudsonM.A.: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J. Urol., 151: 1575–1578, 1994.
8.
FreemanJ.A., LieskovskyG., CookD.W., PetrovichZ., ChenS., GroshenS., SkinnerD.G.: Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (pCN0) prostate cancer from1976 to 1989: intermediate findings. J. Urol., 149: 1029–1034, 1993.
9.
PartinA.W., OesterlingJ.E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358–1368, 1994.
10.
ZinckeH., BergstralhE.J., Larson-KellerJ.J.: Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer, 70 (1): 311–323, 1992.
11.
ChengWS., BergstralhE.J., FrydenbergM., ZinckeH.: Prostate specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome. Eur. Urol., 25: 189–193, 1994.
ZayarsG. K, SandsM.E., PollackA., von EschenbachA.C.: Early androgen ablation for stage D1 (Nl to N3, M0) prostate cancer prognostic variables and outcome. J. Urol., 151: 1330–1333, 1994.
14.
CarterG.E., LieskovskyG., SkinnerD.G., PetrovichZ.: Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J. Urol., 142: 1266–1271, 1989.
